Integra LifeSciences Holdings Corporation (IART)
After hours:
| Previous close | 28.89 |
| Open | 29.52 |
| Bid | 23.10 x 300 |
| Ask | 23.16 x 600 |
| Day's range | 22.36 - 29.74 |
| 52-week range | 22.36 - 51.12 |
| Volume | |
| Avg. volume | 802,431 |
| Market cap | 1.819B |
| Beta (5Y monthly) | 1.14 |
| PE ratio (TTM) | 27.55 |
| EPS (TTM) | 0.84 |
| Earnings date | 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 44.40 |
ZacksIntegra (IART) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Integra (IART) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
GlobeNewswireIntegra LifeSciences Reports First Quarter 2024 Financial Results
PRINCETON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2024. First Quarter 2024 Highlights First quarter revenues of $368.9 million declined 3.1% on a reported basis and declined 2.5% on an organic basis compared to the prior year. Revenue increased 1.6% on an organic basis excluding BostonFirst quarter GAAP earnings per diluted
GlobeNewswireIntegra LifeSciences to Spotlight CereLink® Intracranial Pressure (ICP) Monitoring System at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting
Visit the Codman Specialty Surgical booth to learn how the CereLink ICP Monitoring System provides patients with uncompromised advanced continuous ICP monitoring. CereLink ICP Monitoring Sytem CereLink ICP Monitoring System will be highlighted in booth #655 at AANS Annual Meeting in Chicago, Illinois. PRINCETON, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is pleased to announce that following a su
